CD19 and acute lymphoblastic leukemia: Blinatumomab is a bispecific T-cell engager, which binds simultaneously to CD3-positive cytotoxic T-cells and CD19-positive B-cells, allowing the patient’s endogenous T-cells to recognize and eliminate CD19-positive B-ALL blasts [7,8].